CanSino Biologics (06185.HK): The new drug application for Td5cp for adolescents and adults has been accepted.

Zhitong Finance APP News, CanSino Biologics (06185.HK) announced that the new drug application (NDA) for its developed Adsorbed Acellular Hundred (Five Components) Diphtheria-Tetanus-Pertussis Combined Vaccine (for people aged 6 and above) (Td5cp for adolescents and adults) has recently received the acceptance notice from the National Medical Products Administration of the People's Republic of China.